

podstatně ovlivnit i pacientovo globální hodnocení choroby. Při sledování pacientů s RA však nelze zapomínat ani na další závažné

choroby (karcinom prsu, prostaty), které se vyskytují v míře srovnatelné s běžnou populací.

PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Podpořeno MZ ČR RVO FNOL-0098892 a IGA_LF_2024_004. **Registrace v databázích:** N/A. **Projednání etickou komisí:** N/A.

LITERATURA

1. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis*. 2003;62:722.
2. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. *J Rheumatol*. 2011;8:983.
3. Guellerc D, Cozien S, Ruysen-Witrand A, et al. Prevalence and clinical significance of extra-articular manifestations at diagnosis in the ESPOIR cohort with recent-onset arthritis. *Semin Arthritis Rheum*. 2020;50:409.
4. Chandrashekhara S, Shobha V, Dharmarand BG, et al. Reduced incidence of extra-articular manifestations of RA through effective disease control: Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study. *Int J Rheum Dis* 2017; 20:1694.
5. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum*. 1994;4:481-494.
6. Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. *Rheumatology (Oxford)* 2018;57:1453.
7. Turk MA, Hayworth JL, Nevskaya T, Pope JE. Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. *J Rheumatol*. 2021;48:25.
8. Silva B, Cardozo J, Marback P, Machado F, Galvão V, Santiago M. Peripheral ulcerative keratitis: a serious complication of rheumatoid arthritis. *Rheum Int*. 2010;30(9):1267-8.
9. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. *Scand J Rheumatol*. 2004;33:65.
10. Kimbrough BA, Crowson CS, Davis JM 3rd, et al. Decline in Incidence of Extra-Articular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study. *Arthritis Care Res (Hoboken)* 2024;76:454.
11. Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. *Pharmacotherapy*. 2002;22:1157.
12. Maldonado I, Eid H, Rodriguez GR, et al. Rheumatoid nodulosis: is it a different subset of rheumatoid arthritis? *J Clin Rheumatol*. 2003;9:296.
13. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. *Semin Arthritis Rheum*. 2006;35:368.
14. Lawry GV, Finerman ML, Hanafee WN, et al. Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. *Arthritis Rheum*. 1984;27:873.
15. Greco A, Fusconi M, Macri GF, et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. *Am J Otolaryngol*. 2012;33:753.
16. Devouassoux G, Cottin V, Lioté H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. *Eur Respir J*. 2009;33:1053.
17. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. *Radiology*. 1994;193:375.
18. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. *Arthritis Rheum*. 2010;62:1583-1591.
19. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. *Ann Rheum Dis*. 2017;76:1700-1706.
20. Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. *Respiration*. 2019;98:455-460.
21. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. *Eur Respir Rev*. 2021 Jun 23;30(160):210011.
22. Mertz P, Wollenschlaeger C, Chasset F, et al. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era. *Autoimmun Rev*. 2023;22:103391.
23. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. *Rheumatology (Oxford)* 2008;47:350.
24. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. *Am J Kidney Dis*. 2014;63:206.
25. Sim MK, Kim DY, Yoon J, Park DH, Kim YG. Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms. *Ann Rehabil Med*. 2014 Apr;38(2):249-55.
26. Owlia MB, Newman K, Akhtari M. Fely's Syndrome, Insights and Updates. *Open Rheumatol J*. 2014 Dec 31;8:129-36.
27. Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Fely syndrome. *Ann Intern Med*. 1994;120:35.
28. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum*. 1994;4:481-494.
29. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis*. 2014;1:62-68.
30. Oreská S, Tomčík M. KV riziko u revmatických onemocnění. *Cas Lek Cesk*. 2016;155(6):324-332.
31. Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. *J Rheumatol*. 2019 Jun;46(6):564-571.
32. Rollefstad S, Ikdahl E, Wibetoe G, et al. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. *Eur Heart J Cardiovasc Pharmacother*. 2022;6:539-548.
33. Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. *RMD Open*. 2021;2:e001724. doi: 10.1136/rmdopen-2021-001724.
34. Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. *J Rheumatol*. 2020;3:316-324.
35. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Annals of the Rheumatic Diseases* 2017;76:17-28.
36. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. *Ann Rheum Dis*. 2022 Jun;81(6):768-779.
37. Omair MA, Alkheib SA, Ezzat SE, et al. Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. *Open Access Rheumatol*. 2022 Oct 17;14:231-242.
38. Thomas K, Vassilopoulos D. Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. *Mediterr J Rheumatol*. 2020 Jun 11;31(Suppl 1):129-136.
39. Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. *RMD Open*. 2019;1:e000935. doi: 10.1136/rmdopen-2019-000935.
40. Accortt NA, Lesperance T, Liu M, et al. Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2018 May;70(5):679-684. doi: 10.1002/acr.23426. Epub 2018 Mar 11.
41. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum*. 2008;59:1074.
42. Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. *Rheumatology (Oxford)* 2019;58:1755.
43. Beydon M, Pinto S, De Rycke Y, et al. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. *Lancet Reg Health Eur*. 2023 Oct 30;35:100768.
44. Lange E, Bizzard L, Venn A, et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. *Rheumatology (Oxford)*. 2016 Sep;55(9):1594-600.
45. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. *Clin Rheumatol*. 2020 Mar;39(3):769-778.

**Další literatura u autorky
a na www.casopisvnitrnilekarstvi.cz**